著者 |
石原 俊治
医学部内科学講座内科学第二
三島 義之
医学部内科学講座内科学第二
川島 耕作
医学部内科学講座内科学第二
|
内容記述(抄録等) | Crohn’s disease (CD) is an immune-mediated inflammatory intestinal disease of unknown etiology. In addition to conventional drugs such as 5-aminosalicylates (5-ASA), corticosteroids, and immune-modulating drugs, biologics targeting inflammation- and immunerelated molecules have been developed for treating CD. Initially, anti-tumor necrosis factor (TNF)-α antibodies were used for induction and maintenance therapies, and the clinical course of affected patients was dramatically changed because of their efficacy and safety. More recently, novel humanized biologics targeting the p40-subunit of interleukin (IL)-12/23 and α4β7-integrin have been developed, and shown to contribute to longterm therapy for CD. Although the efficacy of biologics for CD is widely recognized, how to determine which biologic is appropriate for individual patients remains largely unknown and additional studies are necessary to clarify this issue.
|
主題 | cystatin C
protease inhibitor
cerebrospinal fluid
inflammatory neurological diseases
neurodegenerative diseases
|
掲載誌情報 |
Shimane Journal of Medical Science
37
( 2
), 45
- 50
, 2020-06
|
出版者 | Faculty of Medicine, Shimane University
|
権利関係 | Faculty of Medicine, Shimane University
|